Oct 5, 2026 08:02AM
Oct 5, 2026 08:00AM
Oct 2, 2026 08:01AM
Oct 2, 2026 08:00AM
Sep 30, 2026 08:04AM
Sep 30, 2026 08:00AM
Aug 26, 2026 08:32AM Celcuity files sNDA for gedatolisib in PIK3CA mutant breast cancer
Aug 26, 2026 08:30AM
Aug 17, 2026 07:12AM
Aug 17, 2026 04:16AM
Aug 13, 2026 04:06PM
Aug 6, 2026 08:34AM
Jul 30, 2026 08:30AM
Jul 30, 2026 08:30AM Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Jul 15, 2026 07:36AM
Jul 15, 2026 07:23AM
Jul 15, 2026 07:22AM
Jul 14, 2026 04:53PM
Jul 14, 2026 04:53PM
Jun 3, 2026 10:13PM
Jun 3, 2026 10:13PM Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Jun 3, 2026 07:19AM
Jun 3, 2026 07:19AM
Jun 2, 2026 08:26AM
Jun 2, 2026 08:25AM
Jun 2, 2026 08:11AM
May 18, 2026 07:05AM
May 14, 2026 04:01PM Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026 07:30AM
May 14, 2026 07:30AM
May 1, 2026 05:03PM
May 1, 2026 05:03PM
Mar 25, 2026 04:01PM
Mar 9, 2026 05:42PM
Mar 9, 2026 05:42PM Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Feb 12, 2026 04:05PM
Feb 12, 2026 04:05PM
Jan 20, 2026 07:30AM
Jan 20, 2026 07:30AM
Jan 8, 2026 12:08PM
Dec 11, 2025 02:35PM
Dec 11, 2025 02:35PM Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
Nov 17, 2025 04:05PM
Nov 12, 2025 04:01PM
Oct 18, 2025 04:30AM
Oct 18, 2025 04:30AM
Sep 9, 2025 04:01PM
Sep 9, 2025 04:01PM
Aug 27, 2025 04:05PM Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
Aug 18, 2025 06:47AM

334,267 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All